TLSA News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

TL

Mkt Cap

$133.6M

Volume

533.15K

Next Earnings

N/A

Chart Financials Earnings News About Insider Filings

Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis TrialTiziana Life Sciences announced completion of patient enrollment in its Phase 2a randomized, double-blind, placebo-controlled trial (INFORM-MS) evaluating intranasal foralumab in 48 patients with non-active Secondary Progressive Multiple Sclerosis. Topline data is expected in late Q3 2026 and will be presented at the ACTRIMS/ECTRIMS meeting in October 2026. The trial includes a six-month open-label extension phase to assess long-term safety and sustained benefit.GlobeNewswire Inc. · May 21, 2026

Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive FunctionTiziana Life Sciences announced positive preclinical data published on bioRxiv showing that intranasal foralumab, an anti-CD3 monoclonal antibody, significantly reduces neuroinflammation and improves cognitive function in a Long COVID mouse model. The study, conducted by researchers from Yale University and Harvard Medical School, demonstrated that the treatment increases regulatory T cells in the brain, restores neurogenesis, and rescues cognitive deficits. The company is advancing foralumab through clinical trials for multiple neurological conditions including multiple sclerosis, Alzheimer's disease, and ALS.GlobeNewswire Inc. · Apr 16, 2026

Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary SharesTiziana Life Sciences (NASDAQ: TLSA) closed an oversubscribed $8.8 million registered direct offering of 7.04 million ordinary shares at $1.25 per share, with warrants providing up to $10.56 million in additional potential proceeds. The offering was led by CEO Ivor Elrifi and Executive Chairman Gabriele Cerrone. Proceeds will fund Phase 2 clinical trials for intranasal foralumab in na-SPMS and MSA patients.Benzinga · Jan 16, 2026

Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary SharesTiziana Life Sciences closed an oversubscribed $8.8 million registered direct offering of 7.04 million ordinary shares at $1.25 per share, with warrants providing up to $10.56 million in additional potential proceeds. The funding will support completion of Phase 2 clinical trials for intranasal foralumab in na-SPMS and MSA patients. CEO Ivor Elrifi and Executive Chairman Gabriele Cerrone made significant purchases, demonstrating insider confidence.GlobeNewswire Inc. · Jan 16, 2026

Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer’s TrialTiziana Life Sciences is launching a Phase 2 clinical trial for intranasal foralumab to treat early Alzheimer's disease, targeting neuroinflammation in combination with existing anti-amyloid therapies like Leqembi.GlobeNewswire Inc. · Dec 12, 2025

Tiziana Life Sciences to Present at the 37th Annual Roth ConferenceTiziana Life Sciences, a biotechnology company, announced that its CEO will present at the 37th Annual ROTH Conference. The company's lead development candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, has shown promising results in an open-label expanded access program and is currently being studied in a Phase 2a trial for non-active secondary progressive multiple sclerosis.GlobeNewswire Inc. · Mar 17, 2025

Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3Tiziana Life Sciences announced positive results from preclinical studies using its nasal anti-CD3 monoclonal antibody in treating traumatic spinal cord injury. The treatment demonstrated notable improvements in motor function, highlighting its potential as a transformative therapeutic approach.GlobeNewswire Inc. · Jan 23, 2025

Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study DataTiziana Life Sciences, a biotechnology company, will participate in the BIO-Europe 2024 conference to discuss recent clinical progress, including positive data from its combination study involving Ozempic, a GLP-1 agonist. The company aims to engage with industry leaders, potential collaborators, and investors to accelerate the development of its therapeutic pipeline.GlobeNewswire Inc. · Nov 1, 2024

Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 MillionTiziana Life Sciences announced a $5 million registered direct offering, with an option for an additional $5 million. The company plans to use the proceeds to fund clinical trials for its lead candidate, intranasal foralumab, in multiple sclerosis and Alzheimer's disease.GlobeNewswire Inc. · Oct 31, 2024

Tiziana Receives $3.4 Million in Non-Dilutive FundingNEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough therapies in neurodegenerative disease secondary to active neuroinflammatory processes today announced that it had received non-dilutive funding of $3.4 million and issued a corporate update video available here.GlobeNewswire Inc. · Jun 28, 2024

TL

TLSATiziana Life Sciences Ltd. Common Shares

TLSA

Pay with—

Available Balance0.00

Your PositionYou don't own any TLSA yet.

Related Tickers

Earnings